| A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants (NCT05082285) | GlaxoSmithKline | 2021-11-29 |
| A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults (NCT04886154) | GlaxoSmithKline | 2021-06-14 |
| Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age (NCT04318548) | GlaxoSmithKline | 2020-08-25 |
| Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults (NCT04502693) | GlaxoSmithKline | 2020-08-14 |
| Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants (NCT03621670) | GlaxoSmithKline | 2018-07-27 |
| Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination (NCT02986854) | GlaxoSmithKline | 2016-12-08 |
| Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents (NCT02946385) | GlaxoSmithKline | 2016-11-15 |
| Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine (NCT02639351) | GlaxoSmithKline | 2016-03-01 |
| Safety of 4CMenB Exposure During Pregnancy (NCT02640677) | GlaxoSmithKline | 2016-01-31 |
| Combined Study - Phase 3b MenB Long Term Persistence in Adolescents (NCT02446743) | GlaxoSmithKline | 2015-11-17 |
| Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations (NCT02446691) | GlaxoSmithKline | 2015-07-13 |
| A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158) (NCT02451514) | GlaxoSmithKline | 2015-06-30 |
| Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry (NCT02223637) | GlaxoSmithKline | 2014-09-30 |
| Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan. (NCT02173704) | GlaxoSmithKline | 2014-09-11 |
| Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents (NCT02212457) | GlaxoSmithKline | 2014-08-21 |
| Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants (NCT02106390) | GlaxoSmithKline | 2014-06-05 |
| Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination (NCT01934140) | Pfizer | 2014-04-01 |
| Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine (NCT01939158) | Pfizer | 2013-10-02 |
| The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination (NCT01962207) | Pfizer | 2013-10-01 |
| N. Meningitidis Carriage Study (NCT01808365) | GlaxoSmithKline | 2013-08-02 |
| Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination (NCT01777308) | GlaxoSmithKline | 2013-05-03 |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults (NCT01755689) | GlaxoSmithKline | 2013-01-11 |
| Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. (NCT01682876) | GlaxoSmithKline | 2012-10-07 |
| Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects (NCT01641042) | GlaxoSmithKline | 2012-09-10 |
| Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children (NCT01266993) | GlaxoSmithKline | 2011-01-03 |
| Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years (NCT01235975) | GlaxoSmithKline | 2010-11-30 |
| Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds (NCT01154088) | GlaxoSmithKline | 2010-08-27 |
| Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults (NCT01165242) | GlaxoSmithKline | 2010-08-19 |
| Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines (NCT01144663) | GlaxoSmithKline | 2010-07-01 |
| Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration (NCT00758264) | GlaxoSmithKline | 2008-10-30 |
| The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults (NCT00715910) | GlaxoSmithKline | 2008-07-01 |
| Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects (NCT00661557) | GlaxoSmithKline | 2008-05-19 |
| Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children (NCT00674583) | GlaxoSmithKline | 2008-05-09 |
| Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014 (NCT00614614) | GlaxoSmithKline | 2008-02-13 |
| Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects (NCT00514904) | GlaxoSmithKline | 2007-09-18 |
| Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine (NCT00508261) | GlaxoSmithKline | 2007-08-01 |
| Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers. (NCT00471081) | GlaxoSmithKline | 2007-07-05 |
| Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children (NCT00474266) | GlaxoSmithKline | 2007-06-05 |
| Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects (NCT00464815) | GlaxoSmithKline | 2007-05-02 |
| Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years. (NCT00454909) | GlaxoSmithKline | 2007-04-23 |
| Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612 (NCT00465816) | GlaxoSmithKline | 2007-04-11 |
| Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults (NCT00453986) | GlaxoSmithKline | 2007-04-09 |
| Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612 (NCT00427908) | GlaxoSmithKline | 2007-02-07 |
| Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612 (NCT00390143) | GlaxoSmithKline | 2007-02-01 |
| Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine (NCT00356369) | GlaxoSmithKline | 2006-12-23 |
| Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study (NCT00291343) | GlaxoSmithKline | 2006-02-01 |
| Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years (NCT00290329) | GlaxoSmithKline | 2006-01-14 |
| Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs (NCT00126945) | GlaxoSmithKline | 2005-08-01 |
| Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine (NCT00126984) | GlaxoSmithKline | 2005-07-01 |
| Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 Yrs (NCT00227422) | GlaxoSmithKline | 2005-06-01 |
| Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old (NCT00196976) | GlaxoSmithKline | 2005-03-24 |
| Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs (NCT00196963) | GlaxoSmithKline | 2005-03-01 |
| Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine (NCT00271479) | Epicentre | 2004-06-01 |
| Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years (NCT00196950) | GlaxoSmithKline | 2003-09-01 |
| Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy Toddlers (NCT00135564) | GlaxoSmithKline | 2003-01-01 |
| Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs (NCT00137917) | GlaxoSmithKline | 2002-07-01 |
| Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants (NCT00135486) | GlaxoSmithKline | 2002-03-01 |